Clinical trials sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase breakdown

Conditions studied

Recruiting trials led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

• A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus
  NCT07339332 · Phase: Early Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
  NCT05994274 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
  NCT06106906 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
  NCT06106893 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer
  NCT07689656 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
  NCT06653556 · Phase: Early Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer
  NCT06000917 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
  NCT06946199 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment
  NCT05426135 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
  NCT03573791 · Phase: Not specified · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
  NCT06349343 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
  NCT06367088 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
  NCT07301814 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
  NCT06843629 · Phase: Not specified · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Clinical Study of (A-319) in the Treatment of Active Rheumatoid Arthritis
  NCT07347860 · Phase: Early Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
  NCT06400537 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
• Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
  NCT06357741 · Phase: Not specified · Ages: 45 Years to 75 Years · Sex: All (male and female) · 1 location
• Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
  NCT07470151 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Clinical Trial on the Efficacy and Safety of ALT001 in Osteoarthritis
  NCT07404891 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 75 Years · Sex: All (male and female) · 1 location
• Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach（Radiogenomics-Lung）
  NCT06500312 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• FL-261 Imaging for Cancer Diagnosis and Staging
  NCT07510321 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
  NCT06491472 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis
  NCT06463847 · Phase: Phase 1 · Ages: 50 Years to 70 Years · Sex: All (male and female) · 1 location
• Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis
  NCT07547735 · Phase: Phase 2 · Ages: 40 Years to 70 Years · Sex: All (male and female) · 3 locations
• Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
  NCT07059923 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases
  NCT07090200 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
  NCT07474103 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
  NCT07689643 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
  NCT07031713 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
  NCT06542588 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
  NCT06234007 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
  NCT07552467 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• TIPS With or Without BCAA
  NCT07281846 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• The Clinical Study on the Treatment of Refractory RA With UTAA91 Injection
  NCT07001956 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Union Hospital, Tongji Medical College, Huazhong University of Science and Technology recruiting for?

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 34 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.